MEDICAL DICTIONARY
Estrogen-associated hypercoagulability: Hypercoagulability (a supranormal tendency for blood to clot) occurs as an occasional but serious side effect of estrogen therapy.
The blood clots in this situation are dose-related, that is, they occur more frequently with higher doses of estrogen.
Estrogen therapy preparations (all of which carry this risk) include: - esterified estrogens
- esterified estrogens and methyltestosterone
- estradiol
- estrogens (conjugated) and medroxyprogesterone
- estrogens conjugated
The brand names of the estrogen therapy preparations carrying this risk include: - CLIMARA ( estradiol )
- ESTRACE (estradiol)
- ESTRADERM (estradiol)
- ESTRATAB ( esterified estrogens )
- ESTRATEST ( esterified estrogens and methyltestosterone )
- MENEST ( esterified estrogens )
- OGEN ( estropipate )
- PREMARIN ( estrogens conjugated )
- PREMPHASE (estrogens conjugated and medroxyprogesterone )
- PREMPRO (estrogens conjugated and medroxyprogesterone)
Cigarette smokers on estrogen therapy are at a higher risk than non-smokers for blood clots. Therefore, patients requiring estrogen therapy are strongly encouraged to quit smoking .
|
DISCLAIMER:
Information on this site is provided for informational
purposes and is not meant to substitute for the advice
provided by your own physician or other medical professional.
You should not use the information contained herein
for diagnosing or treating a health problem or disease,
or prescribing any medication. You should read carefully
all product packaging. Not all Canadian drugs, Canada
prescription and Canadian prescription medicine is available
at discount Canadian on line pharmacies. If you have
or suspect that you have a medical problem, promptly
contact your health care provider. Information and statements
regarding diet supplements have not been evaluated by
Health Canada and are not intended to diagnose, treat,
cure, or prevent any disease. All trade and service
marks mentioned on this site are recognized as belonging
to their respective owners.
|
|
|
|
